SOLIGENIX, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
SOLIGENIX, INC. (SNGX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 6.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-31
- SOLIGENIX, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2025 was 6.00%, a 25.93% decline from fiscal 2024.
- SOLIGENIX, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 8.10%, a 305.00% increase from fiscal 2023.
- SOLIGENIX, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 2.00%.
- SOLIGENIX, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was -3.90%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 6.00% 10-K · filed 2026-03-31 | |
| 2024-12-31 | 8.10% 10-K · filed 2026-03-31 | |
| 2023-12-31 | 2.00% 10-K · filed 2025-03-21 | -2.00% 10-K · filed 2024-03-15 |
| 2022-12-31 | -3.90% 10-K · filed 2024-03-15 | |
| 2021-12-31 | -4.30% 10-K · filed 2023-03-31 | |
| 2020-12-31 | 4.80% 10-K · filed 2022-03-29 | |
| 2019-12-31 | 1.80% 10-K · filed 2021-03-30 | |
| 2018-12-31 | 1.10% 10-K · filed 2020-03-30 | |
| 2017-12-31 | -13.90% 10-K · filed 2019-03-26 | |
| 2016-12-31 | -38.80% 10-K · filed 2017-03-27 | |
| 2015-12-31 | -16.30% 10-K · filed 2017-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |